Vertex Pharmaceuticals encountered a challenging first quarter in 2025, as both revenue and non-GAAP profit fell short of ...

When faced with the myriad diseases and equally numerous targets for potential drugs the company could pursue, Kewalramani ...

Vertex Pharmaceuticals locked arms with Ono Pharmaceutical in an exclusive deal to advance povetacicept, targeting B ...

Amid the launch of its non-opioid pain med Journavx, Vertex Pharmaceuticals has begun an awareness-raising blitz focused on acute pain management.. The new campaign stars former NFL quarterback ...

Alyftrek and Journavx — The Two Big Launches. According to JPMorgan analyst Jessica Fye, investors will be laser-focused on the company’s two big launches: Alyftrek and Journavx.

Journavx Gains Early Traction. At the 2025 Napa Valley Biotech Forum, JPMorgan analyst Jessica Fye walked away with a bullish tone after conversations with Vertex CEO Reshma Kewalramani and Senior ...

Enter: Journavx, the first pain medication of its kind approved by the U.S. Food & Drug Administration in 25 years. [READ: Understanding the Impact of Health Conditions and Medications on Seniors] ...

JOURNAVX can cause side effects: The most common side effects for patients treated with JOURNAVX include itching, muscle spasms, increased blood level of creatine phosphokinase, and rash.

With JOURNAVX's approval, physicians now have a new, non-opioid treatment option that delivers effective relief without the risk of dependency, helping to reshape the acute pain treatment landscape.